FrancophonIA/ELRC3.0 huggingface dataset:
English: Alternatively, an initial course of amphotericin B therapy can be administered and then carefully followed by completion of a course of fluconazole therapy.
Maltese: Inkella, jista' jiġi amministrat kors inizjali ta' terapija b'amphotericin B u mbagħad dan jiġi segwit birreqqa bit-twettiq ta' kors ta' kura b'fluconazole.
English: • Relapse of oropharyngeal or oesophageal candidiasis in patients infected with HIV who are at high risk of experiencing relapse.
Maltese: • Rikaduta ta' kandidjażi orofarinġeali jew esofaġeali f'pazjenti infettati bl-HIV li huma f'riskju għoli li jesperjenzaw rikaduta.
English: Oesophageal candidiasis is primarily associated with HIV infection or other forms of immunosuppression in children.
Maltese: Il-kandidjażi fl-esofagu hi primarjament assoċjata mal-infezzjoni HIV jew forom oħra ta' immunosuppressjoni fit-tfal.
English: The CHMP accepted that the supporting data were only for the indication of cryptococcal meningitis which was implemented in the SPC and not the general cryptococcosis indication.
Maltese: Is-CHMP aċċetta li d-dejta ta' appoġġ kienet biss għallindikazzjoni ta' meninġite kriptokokkali li ġiet implimentata fl-SPC u mhux fl-indikazzjoni ġenerali tal-kriptokokkożi.
English: Regarding cryptococcosis the evidence for efficacy of fluconazole in the treatment of cryptococcosis of other sites (e.g. pulmonary and cutaneous cryptococcosis) is limited.
Maltese: Dwar il-kriptokokkożi, il-provi għall-effikaċja ta' fluconazole fil-kura tal-kriptokokkożi ta' postijiet oħra (eż. kriptokokkożi pulmonari u tal-ġilda) huma limitati.
English: Fluconazole has been used to treat invasive candida infections in children.
Maltese: Fluconazole intużat biex tikkura infezzjonijiet ta' candida invażiva fit-tfal.
English: CT13 9NJ
Maltese: Fuljett ta' Tagħrif
English: Doses of 3 mg/Kg in children have proved effective against fungal infections in immunocompromised children and also for the treatment of paediatric patients with serious fungal infections, such as cryptococcal meningitis.
Maltese: Dożi ta' 3 mg/Kg fit-tfal urew li huma effettivi kontra infezzjonijiet fungali fi tfal immunokompromessi u wkoll għall-kura ta' pazjenti pedjatriċi b'infezzjonijiet fungali serji, bħall-meninġite kriptokokkali.
English: N/A
Maltese: ANNESS II
English: The CHMP agreed that fluconazole should be indicated for the treatment of chronic oral atrophic candidiasis (denture sore mouth) if dental hygiene or topical treatment are insufficient.
Maltese: Is-CHMP ikkonkluda li fluconazole huwa prodott mediċinali sikur u effettiv fil-profilassi jew fit-trattament għall-kandidjażi invażiva meta mqabbel ma' terapiji oħra.
English: BLISTER/(Alu/Alu)
Maltese: FOLJA/(Alu/Alu)
English: The absolute bioavailability is greater than 90%.
Maltese: Il-bijodisponibilità assoluta hi aktar minn 90%.
English: 20 tablets 30 tablets 60 tablets 90 tablets 100 tablets
Maltese: 20 pillola 30 pillola 60 pillola 90 pillola 100 pillola
English: Date of first authorisation: 12 September 2008 Date of latest renewal: 9 April 2013
Maltese: Data tal-aħħar tiġdid: 9 t'April 2013
English: TAD Pharma GmbH Heinz-Lohmann-Straße 5 27472 Cuxhaven Germany
Maltese: TAD Pharma GmbH Heinz-Lohmann-Straße 5 27472 Cuxhaven II-Ġermanja
English: The adjusted mean difference was -4.3 points (CI 95% -6.4; -2.1 points, p-value <0.0001).
Maltese: Id-differenza medja aġġustata kienet -4.3 punti (CI 95% -6.4; -2.1 punti, valur p <0.
English: - The other ingredients are mannitol, maize starch, pregelatinised maize starch, povidone K25, colloidal anhydrous silica and magnesium stearate.
Maltese: - Is-sustanzi l-oħra huma mannitol, maize starch, pregelatinised maize starch, povidone K25, colloidal anhydrous silica u magnesium stearate.
English: IJ
Maltese: CJJ
English: KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia TAD Pharma GmbH, Heinz-Lohmann-Straße 5, 27472 Cuxhaven, Germany
Maltese: KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Is-Slovenja TAD Pharma GmbH, Heinz-Lohmann-Straße 5, 27472 Cuxhaven, II-Ġermanja
English: Table 1: Parkinson's disease Body System Very common
Maltese: Tabella 1: Marda ta' Parkinson Sistema talĠisem
English: Augmentation was observed in 11.8% of patients in the pramipexole group (N = 152) and 9.4% of patients in the placebo group (N = 149).
Maltese: L-awmentazzjoni kienet osservata fi 11.8% tal-pazjenti filgrupp ta' pramipexole (N = 152) u f'9.4% tal-pazjenti fil-grupp tal-plaċebo (N = 149).
English: CGI-I responder rates (improved, very much improved) were 51.2% and 72.0% for placebo and pramipexole, respectively (difference 20% CI 95%: 8.1%; 31.8%, p<0.0005).
Maltese: Ir-rati tas-CGI-I ta' dawk li rrispondew (imtejba, imtejba ħafna) kienu 51.2% u 72.0% għall-plaċebo u pramipexole rispettivament (differenza ta' 20% CI 95%: 8.1%; 31.8%, p<0.0005).
English: Blister pack (Alu/Alu foil): 20, 30, 60, 90 or 100 tablets, in a box.
Maltese: Pakkett ta' folji (fojl Alu/Alu): 20, 30, 60, 90 jew 100 pillola, f'kaxxa.
English: What Oprymea contains - The active substance is pramipexole.
Maltese: X'fih Oprymea - Is-sustanza attiva hi pramipexole.
English: Adverse events occurring in at least 5% of patients in the pramipexole group and more common in the pramipexole-treated patients than in patients on placebo were: headache (27.9%, placebo 25.0%), somnolence (7.0%, placebo 5.0%), nausea (18.6%, placebo 10.0%), vomiting (11.6%, placebo 0.0%), upper abdominal pain (7.0%, placebo 5.0%), orthostatic hypotension (9.3%, placebo 5.0%), myalgia (9.3%, placebo 5.0%), sleep disorder (7.0%, placebo 0.0%), dyspnoea (7.0%, placebo 0.0%) and upper respiratory tract infection (7.0%, placebo 5.0%).
Maltese: 0%), rimettar (11.6%, plaċebo 0.0%), uġigħ fin-naħa ta' fuq taż-żaqq (7.0%, plaċebo 5.0%), pressjoni tad-demm baxxa meta wieħed iqum bilwieqfa (9.3%, plaċebo 5.0%), majalġja (9.3%, plaċebo 5.0%), problemi biex torqod (7.0%, plaċebo 0.0%), qtugħ ta' nifs (7.0%, plaċebo 0.0%) u infezzjoni fil-parti ta' fuq tal-apparat respiratorju (7.0%, plaċebo 5.0%).
English: Pharmacotherapeutic group: anti-Parkinson drugs, dopamine agonists, ATC code: N04BC05.
Maltese: Kategorija farmakoterapewtika: mediċini kontra l-marda ta' Parkinson, agonisti ta' dopamine, Kodiċi ATC:
English: Within the system organ classes, adverse reactions are listed under headings of frequency (number of patients expected to experience the reaction), using the following categories: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000); not known (cannot be estimated from the available data).
Maltese: Fil-kategoriji tas-sistemi tal-organi, ir-reazzjonijiet avversi huma elenkati taħt titli ta' frekwenza (numru ta' pazjenti li huma mistennija li jkollhom ir-reazzjoni), bl-użu tal-kategoriji li ġejjin: komuni ħafna (≥ 1/10); komuni (≥ 1/100 sa < 1/10); mhux komuni (≥ 1/1,000 sa < 1/100); rari (≥ 1/10,000 sa < 1/1,000); rari ħafna (< 1/10,000); mhux magħruf (ma tistax tittieħed stima mid-data disponibbli).
English: - Augmentation.
Maltese: - Awmentazzjoni.
English: The absolute bioavailability is greater than 90% and the maximum plasma concentrations occur between 1 and 3 hours.
Maltese: Il-bijodisponibilità assoluta hi aktar minn 90% u l-konċentrazzjonijiet massimi fil-plażma jseħħu wara bejn 1 u 3 sigħat.
English: 7 tablets of Oprymea 1.05 mg
Maltese: 7 pilloli ta' Oprymea 1.05 mg
English: Week 3
Maltese: 3 snin
English: Clinical efficacy and safety in Tourette Disorder
Maltese: Effikaċja klinika u sigurtà fid-Disturb ta' Tourette
English: A decreased body weight by 30 kg results in an increase in Cmax of 45%.
Maltese: Tnaqqis fil-piż talġisem ta' 30 kg jirriżulta f'żieda ta' 45% fis-Cmax.
English: Blister (OPA/Alu/desiccant/PE-Alu foil): 21 prolonged-release tablets (3 blisters of 7 tablets): - 7 prolonged-release tablets of 0.26 mg
Maltese: Folja (fojl tal-OPA/Alu/dessikant/PE-Alu): 21 pillola li jerħu l-mediċina bil-mod (3 folji ta' 7 pilloli): - 7 pilloli li jerħu l-mediċina bil-mod ta' 0.26 mg
English: Inhibitors/competitors of active renal elimination pathway Cimetidine reduced the renal clearance of pramipexole by approximately 34%, presumably by inhibition of the cationic secretory transport system of the renal tubules.
Maltese: Inibituri/kompetituri tal-passaġġ tal-eliminazzjoni renali attiv Cimetidine naqqas it-tneħħija renali ta' pramipexole b'madwar 34%, preżumibilment permezz talinibizzjoni tas-sistema tat-trasport li tnixxi l-ketajins tat-tubuli renali.
English: Boxes of 20, 30, 60, 90 and 100 tablets in blisters of 10 tablets are available.
Maltese: Kaxex ta' 20, 30, 60, 90 u 100 pillola f'folji ta' 10 pilloli huma disponibbli.
English: The usual maintenance dose is 1.05 mg per day.
Maltese: Id-doża normali ta' manteniment hi ta' 1.05 mg kuljum.
English: In a 26 week placebo controlled trial, rebound of RLS symptoms (worsening of symptom severity as compared to baseline) was observed in 10% of patients (14 out of 135) after abrupt discontinuation of treatment.
Maltese: Fi prova li damet 26 ġimgħa, ikkontrollata bi plaċebo, kien osservat rebound ta' sintomi RLS (aggravament fis-severità tas-sintomi meta mqabbel mal-linja bażi) f'10% tal-pazjenti (14 minn 135) wara t-twaqqif f'daqqa tal-kura.
English: CGI-I responder rates (much improved, very much improved) were 50.3% (80/159) and 68.5% (111/162) for placebo and pramipexole, respectively (p = 0.001), corresponding to a number needed to treat (NNT) of 6 patients (95%CI: 3.5, 13.4).
Maltese: Ir-rati ta' dawk li rrispondew għal CGI-I (titjib kbir, titjib kbir ħafna) kienu ta' 50.3% (80/159) u 68.5% (111/162) għal plaċebo u pramipexole, rispettivament (p = 0.001), li jikkorrispondu għal numru meħtieġ għal kura (NNT - needed to treat) ta' 6 pazjenti (95%CI:
English: 7 tablets of Oprymea 0.52 mg
Maltese: 7 pilloli ta' Oprymea 0.52 mg
English: The usual maintenance dose is 1.1 mg per day.
Maltese: Id-doża normali ta' manteniment hi ta' 1.1 mg kuljum.
English: Oprymea with food, drink and alcohol
Maltese: Oprymea ma' ikel, xorb u alkoħol
English: After 26 weeks of treatment, there was an adjusted mean reduction in IRLS total score of 13.7 and 11.1 points in the pramipexole and placebo group, respectively, with a statistically significant (p = 0.008) mean treatment difference of -2.6.
Maltese: Wara 26 ġimgħa ta' kura, kien hemm medja ta' tnaqqis aġġustat medja fil-punteġġ totali tal-IRLS ta' 13.7 u 11.1 punti fil-grupp ta' pramipexole u fil-grupp tal-plaċebo, rispettivament, b'medja ta' differenza filkura ta' -2.6 li kienet statistikament sinifikanti (p = 0.008).
English: "Possible side effects".
Maltese: Effetti sekondarji possibbli 5.
English: Boxes of 10, 30, 90 and 100 tablets in blisters of 10 tablets are available.
Maltese: Kaxxi ta' 10, 30, 90 u 100 pillola f'folji ta' 10 pilloli huma disponibbli.
English: (mg of base)
Maltese: (mg)
English: Pramipexole is bound to plasma proteins to a very low (< 20%) extent, and little biotransformation is seen in man.
Maltese: Pramipexole jeħel ftit ħafna mal-proteini fil-plażma (< 20%), u ftit bijotrasformazzjoni tiġi osservata fil-bniedem.
English: The frequency category is probably not greater than "uncommon".
Maltese: Il-kategorija ta' frekwenza probabbilment mhijiex ikbar minn “mhux komuni”.
English: Table 2: Restless legs syndrome Body System Very common
Maltese: Tabella 2: Sindrome tar-Riġlejn Irrekwieti Sistema talĠisem
English: Neuroleptic malignant syndrome
Maltese: Sindrome malinn newroleptiku
English: Each prolonged-release tablet contains 0.26 mg, 0.52 mg, 1.05 mg, 1.57 mg, 2.1 mg, 2.62 mg or 3.15 mg pramipexole as 0.375 mg, 0.75 mg, 1.5 mg, 2.25 mg, 3 mg, 3.75 mg or 4.5 mg pramipexole dihydrochloride monohydrate, respectively.
Maltese: 1.05 mg, 1.57 mg, 2.1 mg, 2.62 mg jew 3.15 mg ta' pramipexole bħala 0.375 mg, 0.75 mg, 1.5 mg, 2.25 mg, 3 mg, 3.75 mg jew 4.5 mg ta' pramipexole dihydrochloride monohydrate, rispettivament.
English: Oprymea 0.088 mg tablets Oprymea 0.18 mg tablets Oprymea 0.35 mg tablets Oprymea 0.7 mg tablets Oprymea 1.1 mg tablets
Maltese: Oprymea 0.088 mg pilloli Oprymea 0.18 mg pilloli Oprymea 0.35 mg pilloli Oprymea 0.7 mg pilloli Oprymea 1.1 mg pilloli
English: Oprymea 1.1 mg tablets Pramipexole
Maltese: Oprymea 1.1 mg pilloli Pramipexole
English: Other medicines and Oprymea
Maltese: Mediċini oħra u Oprymea
English: Endocrine disorders inappropriate antidiuretic hormone secretion
Maltese: Disturbi fissistema endokrinarja tnixxija mhux kif suppost tal-ormon antidijuretiku
English: Oprymea 0.088 mg tablets Oprymea 0.18 mg tablets Oprymea 0.35 mg tablets Oprymea 0.7 mg tablets Oprymea 1.1 mg tablets Pramipexole
Maltese: Oprymea 0.088 mg pilloli Oprymea 0.18 mg pilloli Oprymea 0.35 mg pilloli Oprymea 0.7 mg pilloli Oprymea 1.1 mg pilloli Pramipexole
English: Very common: - Dyskinesia (e.g. abnormal, uncontrolled movements of the limbs) - Sleepiness - Dizziness - Nausea (sickness)
Maltese: Komuni ħafna: - Diskinesija (eż. movimenti anormali, mingħajr kontroll tad-dirgħajn/riġlejn) - Irqad - Sturdament - Nawseja (dardir)
English: Each tablet contains 0.088 mg, 0.18 mg, 0.35 mg, 0.7 mg or 1.1 mg pramipexole as 0.125 mg, 0.25 mg, 0.5 mg, 1 mg or 1.5 mg pramipexole dihydrochloride monohydrate, respectively.
Maltese: Kull pillola fiha 0.088 mg, 0.18 mg, 0.35 mg, 0.7 mg jew 1.1 mg ta' pramipexole bħala 0.125 mg, 0.25 mg, 0.5 mg, 1 mg jew 1.5 mg ta' pramipexole dihydrochloride monohydrate, rispettivament.
English: 21 prolonged-release tablets: EU/1/08/469/054
Maltese: 21 pilloli li jerħu l-mediċina bil-mod: EU/1/08/469/054
English: Oprymea 0.35 mg tablets
Maltese: Oprymea 0.35 mg pilloli
English: The efficacy of pramipexole (0.0625-0.5 mg/day) with paediatric patients aged 6-17 years with Tourette Disorder was evaluated in a 6-week, double-blind, randomised, placebo-controlled flexible dose study.
Maltese: L-effikaċja ta' pramipexole (0.0625-0.5 mg/kuljum) fuq pazjenti pedjatriċi li kellhom 6-17-il sena bidDisturb ta' Tourette kienet evalwata fi studju li sar fuq doża flessibbli li kien double-blind, li fih ilparteċipanti ntgħażlu b'mod każwali u kkontrollati bi plaċebo.
English: In a cross-sectional, retrospective screening and case-control study including 3,090 Parkinson's disease patients, 13.6% of all patients receiving dopaminergic or non-dopaminergic treatment had symptoms of an impulse control disorder during the past six months.
Maltese: Fi studju cross-sectional, screening retrospettiv u case-control li kien jinkludi 3,090 pazjenti bil-marda ta' Parkinson, 13.6% tal-pazjenti kollha li kienu qed jirċievu kura dopaminerġika jew mhux dopaminerġika, kellhom sintomi ta' disturb fil-kontroll tal-impulsi matul l-aħħar sitt xhur.
English: Oprymea is indicated in adults for symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome in doses up to 0.54 mg of base (0.75 mg of salt) (see section 4.2).
Maltese: Oprymea hu indikat fl-adulti għall-kura sintomatika tas-Sindrome tar-Riġlejn Irrekwieti idjopatiku li jkun minn moderat sa sever f'dożi sa 0.54 mg ta' bażi (0.75 mg ta' melħ) (ara sezzjoni 4.2).
English: Oprymea 0.7 mg tablets
Maltese: Oprymea 0.7 mg pilloli
English: You should avoid taking Oprymea together with antipsychotic medicines.
Maltese: Għandek tevita li tieħu Oprymea flimkien ma' mediċini antipsikotiċi.
English: - Sleepiness and episodes of suddenly falling asleep - Psychosis (e.g. comparable with symptoms of schizophrenia) - Vision impairment.
Maltese: - Irqad u episodji li torqod għal għarrieda - Psikosi, (eż. komparabbli ma' sintomi tal-iskiżofrenja) - Indeboliment fil-vista.
English: 1 tablet Oprymea 0.35 mg and 1 tablet Oprymea 0.18 mg
Maltese: 1 pillola ta' Oprymea 0.35 mg u 1 pillola ta' Oprymea 0.18 mg JEW
English: Oprymea 0.18 mg tablets
Maltese: Oprymea 0.18 mg pilloli
English: Rare may affect up to 1 in 1,000 people
Maltese: Rari jistgħu jaffettwaw sa persuna 1 minn kull 1,000
English: Therefore, medicinal products that are inhibitors of this active renal elimination pathway or are eliminated by this pathway, such as cimetidine, amantadine, mexiletine, zidovudine, cisplatin, quinine, and procainamide, may interact with pramipexole resulting in reduced clearance of pramipexole.
Maltese: Għalhekk, prodotti mediċinali li huma inibituri ta' dan il-passaġġ attiv tal-eliminazzjoni renali, jew li jkunu mneħħija permezz ta' dan il-passaġġ, bħal cimetidine, amantadine, mexiletine, zidovudine, cisplatin, quinine, u procainamide, jistgħu jinteraġixxu ma' pramipexole, u dan jirriżulta fi tneħħija mnaqqsa ta' pramipexole.
English: Psychiatric disorders insomnia abnormal dreams restlessness confusion hallucinations libido disorder delusion hyperphagia paranoia mania delirium behavioural symptoms of impulse control disorders and compulsions (such as: compulsive shopping, pathological gambling, hypersexuality, binge eating)
Maltese: Disturbi psikjatriċi insomnija ħolm mhux normali irrekwitezza konfużjoni alluċinazzjonijiet disturb fil-libido delużjoni iperfaġija paranojja manija delirju sintomi fl-imġiba ta' disturbi filkontroll tal-impulsi u lkompulsjonijiet (bħal: xiri kompulsiv logħob tal-azzard patoloġiku, ipersesswalità, teħid ta' ammonti kbar ta' ikel fi żmien qasir)
English: Axial dystonia including antecollis, camptocormia and pleurothotonus (Pisa Syndrome) has occasionally been reported in patients with Parkinson's disease following initiation or incremental dose increase of pramipexole.
Maltese: Distonja axjali, inkluż l-antecollis, il-camptocormia u l-pleurothotonus (il-Marda ta' Pisa) xi kultanti ġiet irrappurtata f'pazjenti bil-marda tal-Parkinson, wara inizjazzjoni jew żieda fid-doża inkrimentali ta' pramipexole.
English: Parkinson's disease, most common adverse reactions The most commonly (≥5%) reported adverse drug reactions in patients with Parkinson's disease more frequent with pramipexole treatment than with placebo were nausea, dyskinesia, hypotension, dizziness, somnolence, insomnia, constipation, hallucination, headache and fatigue.
Maltese: Il-marda ta' Parkinson, l-iktar reazzjonijiet avversi komuni L-aktar reazzjonijiet avversi għall-mediċina (≥ 5%) irrappurtati b'mod komuni f'pazjenti bil-marda ta' Parkinson li kienu aktar frekwenti bil-kura bi pramipexole milli bil-plaċebo kienu nawseja, diskinesija, pressjoni tad-demm baxxa, sturdament, ngħas, nuqqas ta' rqad, stitikezza, alluċinazzjonijiet, uġigħ ta' ras u għeja kbira.
English: Dopamine agonist withdrawal syndrome including apathy, anxiety, depression, fatigue, sweating and pain
Maltese: Sindrome tattwaqqif ta' agonist ta' dopamine inkluż apatija, ansjetà, depressjoni, għeja, għaraq u wġigħ
English: 1 tablet Oprymea 0.35 mg OR
Maltese: 1 pillola ta' Oprymea 0.35 mg
English: If renal function declines during maintenance therapy the Oprymea daily dose should be reduced by the same percentage as the decline in creatinine clearance, i.e. if creatinine clearance declines by 30%, then the Oprymea daily dose should be reduced by 30%.
Maltese: Jekk il-funzjoni renali tonqos matul it-terapija ta' manteniment, id-doża ta' kuljum ta' Opymea għandha titnaqqas bl-istess perċentwali bħat-tnaqqis fit-tneħħija tal-krejatinina, i.e. jekk it-tneħħija tal-krejatinina tonqos bi 30%, allura d-doża ta' kuljum ta' Oprymea għandha titnaqqas bi 30%.
English: Oprymea 0.35 mg tablets Pramipexole
Maltese: Oprymea 0.35 mg pilloli Pramipexole
English: Symptoms suggestive of neuroleptic malignant syndrome have been reported with abrupt withdrawal of dopaminergic therapy (see section 4.2).
Maltese: Sintomi li jissuġġerixxu sindrome malinn newroleptiku kienu rrappurtati mat-twaqqif f'daqqa tatterapija dopaminerġika (ara sezzjoni 4.2).
English: Repeated dose toxicity studies showed that pramipexole exerted functional effects, mainly involving the CNS and female reproductive system, and probably resulting from an exaggerated pharmacodynamic effect of pramipexole.
Maltese: Studji dwar effett tossiku minn dożi ripetuti wrew li pramipexole ħoloq effetti funzjonali, li primarjament kienu jinvolvu s-CNS u s-sistema riproduttiva fin-nisa, u probabbilment irriżultaw minn effett farmakodinamiku esaġerat ta' pramipexole.
English: Week 1
Maltese: Ġimgħa 1
English: 2 tablets Oprymea 0.18 mg
Maltese: 2 pilloli ta' Oprymea 0.18 mg
English: Reports in the literature indicate that treatment of Restless Legs Syndrome with dopaminergic medicinal products can result in augmentation.
Maltese: Rapporti fil-letteratura medika jindikaw li l-kura tas-Sindrome tar-Riġlejn Irrekwieti bi prodotti mediċinali dopaminerġiċi tista' tirriżulta f'awmentazzjoni.
English: Oprymea 0.088 mg tablets Pramipexole
Maltese: Oprymea 0.088 mg pilloli Pramipexole
English: Insomnia hallucinations abnormal dreams confusion behavioural symptoms of impulse control disorders and compulsions compulsive shopping pathological gambling restlessness hypersexuality delusion libido disorder paranoia delirium binge eating hyperphagia mania
Maltese: Disturbi psikjatriċi insomnija alluċinazzjonijiet ħolm mhux normali konfużjoni sintomi fl-imġiba ta' disturbi filkontroll talimpulsi u lkompulsjonijiet xiri kompulsiv logħob tal-azzard patoloġiku irrekwitezza ipersesswalità delużjoni disturbi fil-libido paranojja delirju teħid ta' ammonti kbar ta' ikel fi żmien qasir iperfaġija manija
English: Each prolonged-release tablet contains 2.62 mg pramipexole (as 3.75 mg pramipexole dihydrochloride monohydrate).
Maltese: Kull pillola li terħi l-mediċina bil-mod fiha 2.62 mg ta' pramipexole (bħala 3.75 mg pramipexole dihydrochloride monohydrate).
English: Oprymea 0.35 mg tablets Each tablet contains 0.35 mg pramipexole (as 0.5 mg pramipexole dihydrochloride monohydrate).
Maltese: Oprymea 0.35 mg pilloli Kull pillola fiha 0.35 mg ta' pramipexole (bħala 0.5 mg pramipexole dihydrochloride monohydrate).
English: In patients with a creatinine clearance between 20 and 50 ml/min, the initial daily dose of Oprymea should be administered in two divided doses, starting at 0.088 mg of base (0.125 mg of salt) twice a day (0.176 mg of base/0.25 mg of salt daily).
Maltese: F'pazjenti bi tneħħija tal-krejatinina bejn 20 u 50 ml/min, id-doża inizjali ta' kuljum ta' Oprymea għandha tingħata f'żewġ dożi maqsumin, li jibdew minn 0.088 mg ta' bażi (0.125 mg ta' melħ) darbtejn kuljum (0.176 mg ta' bażi/0.25 mg ta' melħ kuljum).
English: Oprymea is used to: - treat the symptoms of primary Parkinson's disease in adults.
Maltese: Oprymea jintuża biex: - jikkura s-sintomi tal-marda ta' Parkinson primarja fl-adulti.
English: Each tablet contains 0.088 mg pramipexole (as 0.125 mg pramipexole dihydrochloride monohydrate).
Maltese: Kull pillola fiha 0.088 mg ta' pramipexole (bħala 0.125 mg pramipexole dihydrochloride monohydrate).
English: Oprymea 0.26 mg prolonged-release tablets Oprymea 0.52 mg prolonged-release tablets Oprymea 1.05 mg prolonged-release tablets Oprymea 1.57 mg prolonged-release tablets Oprymea 2.1 mg prolonged-release tablets Oprymea 2.62 mg prolonged-release tablets Oprymea 3.15 mg prolonged-release tablets
Maltese: Oprymea 0.26 mg pilloli li jerħu l-mediċina bil-mod Oprymea 0.52 mg pilloli li jerħu l-mediċina bil-mod Oprymea 1.05 mg pilloli li jerħu l-mediċina bil-mod Oprymea 1.57 mg pilloli li jerħu l-mediċina bil-mod Oprymea 2.1 mg pilloli li jerħu l-mediċina bil-mod Oprymea 2.62 mg pilloli li jerħu l-mediċina bil-mod Oprymea 3.15 mg pilloli li jerħu l-mediċina bil-mod
English: Oprymea 0.7 mg tablets Pramipexole
Maltese: Oprymea 0.7 mg pilloli Pramipexole
English: Oprymea has been associated with sleepiness and episodes of suddenly falling asleep, particularly in patients with Parkinson's disease.
Maltese: Oprymea kien assoċjat ma' ngħas u episodji ta' rqad li jiġi f'daqqa, partikularment f'pazjenti bilmarda ta' Parkinson.
English: Because of possible additive effects, caution should be advised when patients are taking other sedating medicinal products or alcohol in combination with pramipexole (see sections 4.5, 4.7 and section 4.8).
Maltese: Minħabba l-possibbiltà ta' effetti addittivi, għandha tingħata attenzjoni meta l-pazjenti jkunu qed jieħdu prodotti mediċinali sedattivi oħrajn jew alkoħol flimkien ma' pramipexole (ara sezzjonijiet 4.5, 4.7 u 4.8).